This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. For more information see: https://www.neuronext.org/
Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Contact information submitted to the ERC will be used to help connect epilepsy researchers with funding organizations exclusively. Your email will not be sold or shared with organizations unrelated to this effort.
Please enter your email address below. If you are already a member you will be logged in.
If you are not a current member, you will be registered automatically.
Please enter a valid email address.Your email address has been registered. Please check your email for further instructions.
The email address you entered is associated with an existing account.